ClinicalTrials.gg
CompletedNCT02157948Updated Aug 16, 2017Results posted

A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis

A Phase 3 interventional study of Denosumab (CP2) and Denosumab (CP4) in Postmenopausal Osteoporosis, sponsored by Amgen. Completed at 23 sites in 4 countries. Open to female participants aged 55 Years to 100 Years. Per ClinicalTrials.gov, last updated 2017-08-16.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
394
Allocation
Randomized
Ages
55 Years to 100 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 31 studies testing denosumab in Osteoporosis, Postmenopausal — 1 open to participants now, 3 under way, 2 of them phase 3. Denosumab · Osteoporosis, Postmenopausal.

Enrollment
12th of 31
394 · median 278
Started
2014
with 2 others
Phase 3
17 of 31
1 open now
Registered
17th of 31
by date
Lead sponsor
12 of 31
Amgen

Among the 31 studies testing denosumab in Osteoporosis, Postmenopausal, this one is the 12th largest by enrollment, is one of 3 that started in 2014, is one of 17 in phase 3, and was the 17th registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

1 of the 31 studies testing denosumab in Osteoporosis, Postmenopausal is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About denosumab

Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 19 Osteoporosis, Postmenopausal studies recruiting now, 8 (42%) set no upper age limit and 7 (37%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 55 Years to 100 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing denosumab in Osteoporosis, Postmenopausal, or all of them as a file.
02

Study summary

This study will compare the effect of denosumab produced by two different manufacturing processes on bone mineral density at the lumbar spine in postmenopausal women with osteoporosis.

03

Conditions studied

  • Postmenopausal Osteoporosis

Keywords

  • postmenopausal osteoporosis
  • osteoporosis
  • postmenopausal
  • denosumab
  • women
04

Who can participate

Ages eligible
55 Years to 100 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has provided prior to any study-specific activities/procedures
  • Ambulatory women.
  • Age 55 years or older
  • Screening BMD value equivalent to a T-score less than or equal to -2.5 at the lumbar spine, total hip, or femoral neck.

Exclusion criteria

Exclusion Criteria:

  • Administration of osteoporosis treatments or bone active treatments within specific timeframes
  • Vitamin D deficiency
  • Diseases and conditions that affect bone metabolism (e.g., hypo/hyper-parathyroidism; hypo/hyperthyroidism, unless stable and well-controlled)
  • to denosumab therapy (e.g., hypocalcemia)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
394 participants (actual)

Study arms

  • Active comparator
    Denosumab CP2

    Participants received 60 mg denosumab manufactured using the current CP2 process subcutaneously once every 6 months for 1 year.

    Drug: Denosumab (CP2)

  • Experimental
    Denosumab CP4

    Participants received 60 mg denosumab manufactured using the new CP4 process subcutaneously once every 6 months for 1 year.

    Drug: Denosumab (CP4)

Interventions

  • Denosumab produced by a process referred to as CP2, administered subcutaneously from a prefilled syringe.

    Also known as: XGEVA®

  • Denosumab produced by a process referred to as CP4, administered subcutaneously from a prefilled syringe.

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Lumbar Spine BMD

    Lumbar spine bone mineral density (BMD) was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.

    Time frame: Baseline and Month 12

Secondary outcomes

  1. Percent Change From Baseline in Serum Type I Collagen C-telopeptide (sCTX)

    Time frame: Baseline, month 1, month 6 and month 12

  2. Percent Change From Baseline in Serum Procollagen Type 1 N-terminal Propeptide (P1NP)

    Time frame: Baseline, month 1, month 6 and month 12

07

Results

Posted Aug 16, 2017

Participant flow

This study was conducted at 21 centers in Poland, Denmark, United States (US), and Canada. The first participant enrolled on 05 May 2014 and the last participant enrolled on 03 July 2014.

Participant flow — Overall Study
MilestoneDenosumab CP2Denosumab CP4
Started197197
Received treatment196196
Completed188188
Not completed99
Withdrew: Withdrawal by subject45
Withdrew: Lost to follow-up32
Withdrew: Protocol specified criteria21
Withdrew: Decision by sponsor01

Outcome measures

PrimaryPercent Change From Baseline in Lumbar Spine BMD

Lumbar spine bone mineral density (BMD) was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.

Time frame:
Baseline and Month 12
Reported as:
Mean · percent change
Percent Change From Baseline in Lumbar Spine BMD
percent changeDenosumab CP2Denosumab CP4
Percent Change From Baseline in Lumbar Spine BMD5.78 ± 3.445.73 ± 3.08
Statistical analysis
  • Denosumab CP2 vs Denosumab CP4 · ANCOVA · p = < 0.001 (One-sided p-value based on the prespecified non-inferiority margin of -1.44% for lumbar spine.) · Difference from cp2: -0.07 · 95% CI -0.72 to 0.57
  • Denosumab CP2 vs Denosumab CP4 · ANCOVA · p = < 0.001 (Two-sided p-value based on the prespecified equivalence margin of ±1.44% for lumbar spine.) · Difference from cp2: -0.07 · 95% CI -0.72 to 0.57
SecondaryPercent Change From Baseline in Serum Type I Collagen C-telopeptide (sCTX)
Time frame:
Baseline, month 1, month 6 and month 12
Reported as:
Median · percent change
Percent Change From Baseline in Serum Type I Collagen C-telopeptide (sCTX)
percent changeDenosumab CP2Denosumab CP4
Month 1 (n = 195, 193)-86.39 (-90.65 to -78.45)-88.05 (-91.12 to -80.79)
Month 6 (n = 191, 189)-76.46 (-85.58 to -60.58)-79.48 (-87.06 to -66.86)
Month 12 (n = 187, 188)-71.34 (-83.33 to -47.13)-75.44 (-85.88 to -61.90)
SecondaryPercent Change From Baseline in Serum Procollagen Type 1 N-terminal Propeptide (P1NP)
Time frame:
Baseline, month 1, month 6 and month 12
Reported as:
Median · percent change
Percent Change From Baseline in Serum Procollagen Type 1 N-terminal Propeptide (P1NP)
percent changeDenosumab CP2Denosumab CP4
Month 1 (n = 195, 193)-29.59 (-38.06 to -20.02)-29.86 (-38.80 to -20.90)
Month 6 (n = 192, 190)-76.63 (-82.90 to -66.69)-77.74 (-85.02 to -70.31)
Month 12 (n = 186, 188)-71.44 (-77.64 to -57.35)-72.08 (-80.24 to -62.40)

Adverse events

Collected over 12 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Denosumab CP2—13/196 (6.6%)25/196 (12.8%)
Denosumab CP4—6/196 (3.1%)36/196 (18.4%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventDenosumab CP2Denosumab CP4
Carotid artery stenosisNervous system disorders2/1960/196
Ischaemic strokeNervous system disorders2/1960/196
AnaemiaBlood and lymphatic system disorders1/1960/196
ArrhythmiaCardiac disorders1/1960/196
VertigoEar and labyrinth disorders1/1960/196
GoitreEndocrine disorders1/1960/196
Abdominal painGastrointestinal disorders1/1960/196
AppendicitisInfections and infestations0/1961/196
DiverticulitisInfections and infestations1/1961/196
Femur fractureInjury, poisoning and procedural complications1/1960/196
Most frequent other events
Most frequent other events
EventDenosumab CP2Denosumab CP4
NasopharyngitisInfections and infestations15/19621/196
ArthralgiaMusculoskeletal and connective tissue disorders11/19615/196

Baseline characteristics

Age, Continuous
Age, Continuous(years)Denosumab CP2Denosumab CP4Total
Mean68.0 ± 6.868.3 ± 7.368.1 ± 7.0
Age, Customized
Age, Customized(participants)Denosumab CP2Denosumab CP4Total
< 65 years6570135
≥ 65 years132127259
Sex: Female, Male
Sex: Female, Male(Participants)Denosumab CP2Denosumab CP4Total
Female197197394
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Denosumab CP2Denosumab CP4Total
White190195385
Asian415
Native Hawaiian or Other Pacific Islander213
Other101
Lumbar Spine Bone Mineral Density (BMD) Score
Lumbar Spine Bone Mineral Density (BMD) Score(T-score)Denosumab CP2Denosumab CP4Total
Mean-2.75 ± 0.91-2.75 ± 0.75-2.75 ± 0.83
Serum Type I Collagen C-telopeptide (CTX-1)
Serum Type I Collagen C-telopeptide (CTX-1)(ng/mL)Denosumab CP2Denosumab CP4Total
Median0.433 (0.268 to 0.610)0.462 (0.328 to 0.641)0.452 (0.295 to 0.618)
Serum Procollagen Type 1 N-terminal Propeptide (P1NP)
Serum Procollagen Type 1 N-terminal Propeptide (P1NP)(μg/L)Denosumab CP2Denosumab CP4Total
Median56.6 (45.7 to 73.4)61.5 (45.1 to 75.6)59.3 (45.4 to 75.0)
08

Study locations

23 sites
  • Research Site
    Santa Maria, California 93454, United States
  • Research Site
    South Lake Tahoe, California 96150, United States
  • Research Site
    Lakewood, Colorado 80227, United States
  • Research Site
    Gainesville, Georgia 30501, United States
  • Research Site
    Bethesda, Maryland 20817, United States
  • Research Site
    Detroit, Michigan 48236, United States
  • Research Site
    Albuquerque, New Mexico 87106, United States
  • Research Site
    Akron, Ohio 44311, United States
  • Research Site
    Bend, Oregon 97701, United States
  • Research Site
    Duncansville, Pennsylvania 16635, United States
  • Research Site
    Vancouver, British Columbia V5Z 4E1, Canada
  • Research Site
    Westmout, Quebec H3Z 1E5, Canada
  • Research Site
    Quebec, G1V 3M7, Canada
  • Research Site
    Aalborg, 9000, Denmark
  • Research Site
    Ballerup, 2750, Denmark
  • Research Site
    Vejle, 7100, Denmark
  • Research Site
    Bialystok, 15-351, Poland
  • Research Site
    Gliwice, 44-100, Poland
  • Research Site
    Kraków, 31-501, Poland
  • Research Site
    Lodz, 90-368, Poland
  • Research Site
    Lodz, 90-558, Poland
  • Research Site
    Swidnik, 21-040, Poland
  • Research Site
    Warszawa, 04-730, Poland
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2014, a primary completion of Jul 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2017, 2 years 1 month after primary completion. A results delay was requested in Nov 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2014
First posted
Jun 6, 2014
Start
May 2014
Primary completionActual
Jul 2015
CompletionActual
Jul 2015
Results delay requested
Nov 10, 2015
Results first posted
Aug 16, 2017
Last update
Aug 16, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02157948
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jun 6, 2014
Start date
May 2014
Primary completion
Jul 2015
Completion
Jul 2015
Results posted
Aug 16, 2017
Last update
Aug 16, 2017

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion